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AA amyloidosis results from the pathologic deposition in the kidneys and other organs
of ﬁbrils composed of N-terminal fragments of serum amyloid A protein (SAA). Given
that there are only limited means to visualize these deposits, we have developed a
series of mAbs, 2A4, 7D8, and 8G9, that bind speciﬁcally with nanomolar afﬁnity to a
carboxy-terminal epitope generated following proteolysis of SAA that yields the predom-
inant component of AA amyloid deposits. Notably, these antibodies do not recognize
native SAA, they retain their immunoreactivity when radiolabeled with I-125 and, after
injection into AA amyloidotic mice, localize, as evidenced by autoradiography and micro-
single photon emission computed tomography imaging, to histologically conﬁrmed areas
of amyloid deposition; namely, spleen, liver, and pancreas. The results of our in vitro and
in vivo studies demonstrate the AA ﬁbril-selectivity of mAbs 2A4, 7D8, and 8G9 and war-
rant further investigation into their role as novel diagnostic agents for patients with AA
amyloidosis.
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INTRODUCTION
AA amyloidosis is characterized by the pathological deposition
in various body tissues, particularly the kidneys, spleen, and liver
(Gillmore et al., 2001), of ﬁbrils formed from N-terminal frag-
ments of serum amyloid A (SAA) protein. This disorder occurs
in man and various mammalian and avian species, typically as
a consequence of chronic inﬂammation, e.g., rheumatoid arthri-
tis, tuberculosis, Familial Mediterranean fever, etc., that results in
a sustained elevation of the amyloidogenic SAA precursor. The
relentless accumulation of ﬁbrillar proteins in affected tissues
leads to progressive organ failure and eventually death. Experi-
mentally, this disease can be induced in susceptible strains of mice
that are given silver nitrate, casein, or lipopolysaccharide, and also
occurs spontaneously in animals carrying the human IL-6 trans-
gene (Solomon et al., 1999; Wall et al., 2005). Amyloid deposition
in these in vivo models is markedly accelerated by concomitant
intravenous (i.v.) injection or oral administration of miniscule
amounts of AAﬁbrils that serve as a“seed,”i.e., an amyloid enhanc-
ing factor (AEF), to promote ﬁbril formation (Kisilevsky et al.,
1984; Varga et al., 1986; Senthilkumar et al., 2008; Westermark
and Westermark, 2009).
From a clinical standpoint, there is a need for an objec-
tive means to document the extent of AA amyloid deposition
or its resolution in order to ascertain a patient’s response to
treatment and/or if relapse has occurred. In this regard, rou-
tine radiographic techniques (CT, MRI, and ultrasound) are not
particularly informative or “amyloid speciﬁc”; furthermore, the
deposits are rarely visualized using available nuclear medicine
agents. Although European investigators have imaged AA amy-
loid by planar gamma scintigraphy and single photon emission
computed tomography (SPECT) using 123I-labeled serum amy-
loid P-component (Hawkins et al., 1988, 1998; Hazenberg et al.,
2006), this compound is not clinically available in theUnited States
and this technique does not provide quantitative data.
Another strategy involves use of speciﬁc radiolabeled ﬁbril-
reactive antibodies as imaging agents. A precedent for this
approach has been established utilizing mAb 11-1F4, which rec-
ognizes an amyloid ﬁbril-dependent, conformational epitope on
immunoglobulin light chains, but is non-reactive with the natively
folded molecules. This mAb,when radiolabeled with the positron-
emitting isotope I-124, has been shown by PET/CT to image AL
amyloid, ﬁrst in an animal model (Wall et al., 2006a), and then
in patients with AL amyloidosis enrolled in a Phase I clinical trial
(Wall et al., 2010).
Given the necessity to monitor the presence and biodistri-
bution of AA amyloid in the major target organs of patients
with AA amyloidosis, we have developed a series of mAbs, des-
ignated 2A4, 7D8, and 8G9, that bind speciﬁcally to AA ﬁb-
rils, but not the normal circulating precursor protein, and have
deﬁned the structural basis for their speciﬁcity. Notably, these
reagents,when radiolabeledwith I-125,visualizedﬁbrillar deposits
in a transgenic murine model of AA amyloidosis (Solomon
et al., 1999), as shown by micro-SPECT imaging. Based on
the results of our studies, we posit that these antibodies could
be utilized clinically as imaging agents for individuals with AA
amyloidosis.
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MATERIALS AND METHODS
ANTIBODIES
Preparation of the immunogen
A peptide containing amino acids 71–75 of murine SAA,
with two artiﬁcial N-terminal amino acids added for ease of
coupling (CGGHEDT), was synthesized by AnaSpec Inc. The
peptide was conjugated to sheep anti-mouse IgG using N -[e-
Maleimidocaproyloxy]succinimide ester (EMCS) to crosslink the
cysteine to the tertiary amines on lysyl residues in the antibody.
Immunization and fusion
AJ mice (Jackson Labs) were immunized with 50μg of the peptide
conjugate in complete Freund’s adjuvant, followed by boosts 14
and 28 days later with another 50 μg in incomplete Freund’s adju-
vant. Animals were bled on day 35, where the anti-peptide titer, as
determined by ELISA, was >1/10000. Splenocytes from one such
mouse were fused to SP2/0 cells and the resulting hybridomas
screened by ELISA for reactivity to the CGGHEDT component, as
well as for lack of reactivity to a peptide that included an additional
ﬁve downstream residues of the murine SAA sequence (GHEDT-
MADQE). Three hybridomas, 2A4, 7D8, and 8G9, were identiﬁed,
stabilized, and cloned by three rounds of limiting dilution. Anti-
bodies were generated in ascites and following delipidation were
isolated from a 50% (w/v) ammonium sulfate precipitate by cen-
trifugation. The antibody precipitate was dialyzed against PBS and
then puriﬁed on a Protein G column.
Biotinylation of puriﬁed antibodies
Puriﬁed antibodies were diluted to 1mg/ml in PBS and biotiny-
lated using EZ-Link NHS-PEG4-Biotin, No Weigh Format (Ther-
moFisher Scientiﬁc), according to the manufacturer’s speciﬁca-
tions, except that the ratio of biotin to antibody was reduced to a
10-fold molar excess.
MURINE AND HUMAN AA AMYLOID
Murine and human AA amyloid extracts were isolated from amy-
loidotic tissues by a serial ﬂotation procedure, as described previ-
ously (Pras et al., 1968). HumanAAwas kindly provided byDr. Per
Westermark (University of Uppsala, Sweden).All procedures using
human-derived materials were approved by the University of Ten-
nessee Institutional Review Board. AA amyloidosis was induced in
8-week-old transgenic H2-Ld-huIL-6 Tg Balb/c (Wall et al., 2008)
mice by injection into the lateral tail vein of 100 μl PBS containing
100μg of a spleen-derived AA extract.
All animal experiments were performed in accordance with
Institutional Animal Care and Use Committee-approved proto-
cols.
IMMUNOHISTOCHEMISTRY
Six micrometer-thick sections, cut from formalin-ﬁxed, parafﬁn-
embedded tissues, were subjected to antigen retrieval using the
High pH Target Retrieval™ system (Dako). After a 30-min incuba-
tion at 90˚C, followed by 20min at room temperature, the tissues
were immunostained overnight at 4˚C with a 3-μg/ml solution of
biotinylated anti-AA amyloid-speciﬁc mAb in 0.05% Tween/PBS.
The reaction was developed using the Vectastain ABC kit (Vector
Labs). The presence of amyloid was conﬁrmed by staining with a
0.1% alkaline Congo red solution, where the characteristic green
birefringence was seen upon examination using a Leica DM500
light microscope ﬁtted with cross-polarizing ﬁlters. Digital micro-
scopic images were acquired with a cooled CCD camera (SPOT,
Diagnostic Instruments).
ELISA
Wells of NUNC Maxisorb plates (eBioscience) were coated with
extracts of murine AA amyloid ﬁbrils (8 μg/ml) or the two syn-
thetic peptides (3μg/ml) and incubated overnight at 37˚C. The
dried wells were washed ×1 with assay buffer (PBS containing
0.05% Tween 20) and blocked with 200μl of 1% BSA in PBS
at 37˚C for 1 h, followed by addition of the anti-AA amyloid-
speciﬁc and control mAbs titrated in triplicate over the range of
1M× 10−11 M–1M× 10−6 M (to determine background values,
wells were ﬁlled only with antibody). After a 1-h incubation at
37˚C, the wells were washed ×2, ﬁlled with 100 μl of a 1:5000 dilu-
tion of goat anti-mouseHRP conjugate and, following another 1-h
incubation at 37˚C and washes, 100μl of ABTS in 0.06% H2O2
were added. The absorbance at 405 nm was measured 30min later
with a Wallac Victor3 plate reader (PerkinElmer) and the data
analyzed using SigmaPlot (SPSS Inc.).
COMPETITION ELISA
Quadruplicate rows of NUNC Maxisorb wells were coated with
50μl of murine or human renal or splenic AA ﬁbrils suspended
in PBS (8μg/ml), the plates dried overnight at 37˚C, and the wells
blocked for 1 h at 37˚C with 1% BSA/PBS (200μl/well). The AA
samples used for competition were suspended in assay buffer con-
taining 1% BSA to make a 2× stock solution (800μg/ml) and then
serially diluted to a ﬁnal concentration of 1× 10−11 M. Anti-AA
amyloid-speciﬁc and control mAbs were diluted with assay buffer
to form a 2× stock solution and added to the human and murine
AA ﬁbril preparations to yield a ﬁnal concentration of 50 nM and
a starting 400μg titer of competitor. Next, the competitor-mAb
solutions were transferred to the AA ﬁbril-coated plates and left
for 1 h at 37˚C [to establish maximum binding, one row of wells
contained mAb alone (no competitor) and non-speciﬁc (back-
ground) binding was measured in those with antibody, but no
ﬁbrils]. After two washes, 100μl of a 1:5000 dilution of goat anti-
mouse HRP-conjugated secondary antibody was added and the
plates incubated for 1 h at 37˚C, washed, and the reaction devel-
oped by addition of 100μl of ABTS in 0.06% H2O2. After 30min,
the absorbance was measured at 405 nm with the microplate
reader. Data were analyzed using Excel and SigmaPlot, with each
point representing the mean of triplicate values corrected for
non-speciﬁc binding.
RADIOLABELING
Forty nanomolar of anti-AA and control mAbs were labeled
with 2mCi of reductant-free 125I (Perkin Elmer), using limiting
amounts of chloramine T (Wall et al., 2006b). The reaction was
quenched with a two-fold molar excess of sodium metabisulﬁte
and the labeled reagents were then suspended in PBS contain-
ing 5mg/ml BSA; unbound isotope and protein aggregates were
removed by size-exclusion liquid chromatography via an Ultro-
gel AcA34 column (Amersham Pharmacia). Fractions containing
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FIGURE 1 | Amino acid sequences of AA amyloid from five mammalian species.The ﬁve-residue murine C-terminal AA peptide, GHEDT, spanning residues
71–75 and used as immunogen to generate mAbs 2A4, 7D8, and 8G9 is underlined (the cheetah, cat, and dog proteins contain an 8-amino acid insertion
between positions 65 and 66).
FIGURE 2 | Interactions of mAbs 2A4, 7D8, and 8G9 with murine and
humanAA amyloid and synthetic AA-related peptides. (A) Binding of 2A4,
7D8, and 8G9 using GHEDT (ﬁlled) or, as a control for full length SAA, the
GHEDTMADQE peptide (open), as substrate in the ELISA. (B,C) Reactivity of
the three mAbs with murine or human AA amyloid extracts, respectively.
(D–F) Competitive inhibition of binding of mAbs 2A4, 7D8, and 8G9 to human
and (G–I) murine AA amyloid in the absence (◦) or presence (•) of increasing
concentrations of the heterologous AA extract.
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the IgG monomer were pooled for imaging experiments. Radi-
olabeling efﬁciency was qualitatively assessed by Cyclone phos-
phor imaging (Packard Instruments) of 125I-labeled mAb in 10%
SDS-PAGE gels, under native and reducing conditions.
MICRO-SPECT/CT
The biodistribution of the radiolabeled mAbs was determined in
groups composed of three control or amyloidotic mice. Each ani-
mal was injected with 6μg of 125I-labeled mAb (∼150μCi) in
the lateral tail vein and, after 48 or 72 h, given a 200-μl i.v. dose
of Fenestra VC™ (Advanced Research Technologies). Thirty min-
utes later, the mice were euthanized by isoﬂurane overdose and
SPECT/CT images acquired.
Single photon emission computed tomography data were col-
lected with a microCAT II+ SPECT dual modality imaging appa-
ratus equipped with a 1-mm-pore diameter pinhole collimator
(Siemens Preclinical Solutions). For imaging, the two detectors
(composed of a 50-mm-diameter Hamamatsu R2486-02 multi-
anodephoto-multiplier tube coupled to a 1-mm× 1-mm× 8-mm
CsI (Tl) crystal array arranged on a 1.2-mm2 grid) were posi-
tioned ∼45mm from the center of rotation. Each SPECT dataset
comprised 45 projections collected over 360˚ during the course
of ∼50min. Images were reconstructed using an implementation
of the expectation maximization–maximum likelihood (EM–ML)
algorithm.
After acquisition of SPECT data, high-resolution CT images
were obtained with the microCAT II scanner that had a circular
orbit cone beam geometry and was equipped with a 20- to 80-kVp
microfocus X-ray source that captured a 90-mm× 60-mm ﬁeld of
view using a 2048× 3072 CCD array detector. Each CT dataset,
composed of 360 projections at 1˚ azimuths, was procured over
8min. Images were reconstructed in real-time on isotropic 77-μm
voxels using an implementation of the Feldkamp backprojection
algorithm.To facilitate co-registration of the reconstructed SPECT
and CT images, Co-57-sealed sources were placed on the imaging
bed and datasets were visualized and co-registeredmanually with a
3-D image analysis software package (Amira,Version 3.1: Mercury
Computer Systems).
BIODISTRIBUTION
Tissue samples harvested from AA amyloid-bearing and control
mice injected with the 125I-labeled mAbs were placed into tared
vials, weighed, and the radioactivity measured. The primary index
values were expressed as % injected dose/g tissue (% ID/g).
AUTORADIOGRAPHY
Six micrometer-thick sections cut from formalin-ﬁxed, parafﬁn-
embedded blocks of tissue obtained from mice sacriﬁced 48 h
post-injection of 125I-labeled mAb were placed on Probond
microscopic slides (ThermoFisher), dipped in NTB-2 emul-
sion (Eastman Kodak), stored in the dark, and developed
after a 96-h exposure. The sections were counterstained with
hematoxylin and eosin, cover-slipped with Permount (Ther-
moFisher), and examined by light microscopy. In addition, con-
secutively cut sections were stained with Congo red and viewed
under cross-polarized illumination or immunostained using the
Table 1 | Binding of mAbs to AA amyloid extracts and synthetic AA
peptides.
mAb EC50 values
Amyloid extracts Synthetic peptides
Mouse AA
(nM)
HumanAA
(nM)
HEDT
(nM)
HEDTMADQ
(nM)
2A4 4.09 26.4 3.4 >>100
7D8 1.84 13.3 2.3 >>100
8G9 5.64 31.7 4.0 >>100
FIGURE 3 | Dependency on residues E73 and D74 for the high-affinity
binding of anti-AA fibril-specific mAbs. Measurement by ELISA of the
reactivity of mAbs 2A4 (A) 7D8 (B) and 8G9 (C) at different concentrations
against microplate well adsorbed peptides (•, HEDT; ◦, AEDT; , HADT;
, HEAT; , HEDA; , HEDTMADQE).
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AA-reactive mAbs as primary reagents. Digital photographs were
taken and evaluated with the Image Pro Plus software package
(MediaCybernetics).
RESULTS
The primary structures of mouse, human, and three other mam-
malian AA proteins are provided in Figure 1. To generate mAbs
speciﬁc for the AA amyloid ﬁbril, a 7-amino acid peptide con-
taining the 5 carboxy-terminal residues (GHEDT) of the cleaved
murine SAA that forms AA amyloid ﬁbrils was used as the
immunogen and the resultant mAbs were screened for reactivity
against this component. Three monoclonal antibodies, designated
2A4, 7D8, and 8G9 (all of the IgG2 isotype), exhibited saturable
binding over a molarity of 10−7–10−11 M, with EC50 values of
3.4, 1.84, and 4.0 nM, respectively (Figure 2A). In contrast, there
was no afﬁnity observed, even at 10−7 M, when the mAbs were
titrated over the same concentration range using, as substrate, the
longer peptide, GHEDTMADQE, that contained an additional
FIGURE 4 | Immunostaining of human and murine AA deposits by mAbs 2A4, 7D8, and 8G9. (A) Interaction of the antibodies with AA amyloid contained
in sections of H2-Ld-huIL-6 mouse-derived spleen and liver, as well as human kidney, compared favorably with the distribution of amyloid evidenced by Congo
red staining. (B) Binding of mAb 2A4 absorbed with (upper) the GHEDTMADQE peptide or (lower) the GHEDT immunogen. Original magniﬁcations, ×40.
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ﬁve residues not present in the AA ﬁbrils. To determine if the
interaction of the mAbs with AA amyloid was similar to that of
the immunizing peptide, mouse and human AA amyloid extracts
were adsorbed onto microplate wells and antibody reactivity mea-
sured by ELISA (Figures 2B,C). In both cases, the three reagents
bound with saturation values of <10−7 M; however, there was
greater afﬁnity for mouse AA, with EC50s comparable to that for
the GHEDT peptide (Table 1). Similar binding signal amplitudes
were observed for mouse AA and the GHEDTMADQE molecule,
indicating an equivalent epitope density. For human AA amyloid,
the EC50s were ∼10–30 nM. Notably, irrespective of the substrate
(GHEDT peptide, mouse or human AA), the binding of the three
mAbs varied, i.e., 7D8> 2A4> 8G9, with 7D8 having a three-fold
lower EC50 than 8G9.
To ensure that the interaction of the mAbs with AA ﬁbrils did
not result froman“artiﬁcial”neo-epitope formed as a consequence
of adsorbing the material onto the microplate well, competitive
binding studies were performed using soluble mouse and human
AA extracts (Figures 2D–I). In these studies, although both were
capable of inhibitingmAbbinding to the heterologousAAamyloid
on the microplate, the murine AA was more effective, as evi-
denced by the ﬁnding that the IC50 for 7D8 binding to human
AA, when mouse AA was used as a competitor, was 27 versus
15 and 18μg/ml for mAbs 2A4 and 8G9, respectively. Similarly,
as compared to 2A4 and 8G9, 7D8 required four- and seven-fold
more soluble humanAA extract to achieve 50% inhibition of bind-
ing. These data were consistent with the stronger afﬁnity of mAb
7D8 to the GHEDT peptide, as well as to murine and human AA
amyloid.
Although the mAbs were generated using the murine SAA
GHEDT peptide as the immunogen, all showed high avidity for
mouse and human AA amyloid with slightly higher afﬁnity for
the murine (HEDT) versus human (AEDS) sequences. To better
understand the nature of the antibody binding sites,we performed
FIGURE 5 | Radioimmunoimaging of AA amyloid. SPECT/CT images
obtained 48 h after AA amyloidotic mice were injected with ∼250μCi of
125I-labeled mAbs 2A4, 7D8, 8G9, or the isotype-matched control antibody,
MOPC 141. Accumulation of the radioiodinated antibodies in amyloid-laden
liver (L) and spleen (S) is indicated, as is uptake of free iodide in the thyroid (T)
of a mouse given the control mAb.
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studies using alanine (Ala)-substituted peptides as substrates in
the ELISA (Figure 3). mAb 2A4 boundAEDT and HEDA peptides
equally well, with an EC50 equivalent to that of the unmodiﬁed
HEDT molecule. In contrast, substitution of Ala for Glu in the
HADT sequence resulted in a shift in the EC50 from∼3 to 100 nM
(Figure 3). Furthermore, reactivity was completely abrogated by
replacement of Ala for the Asp residue (HEAT). Disruption of
the binding to both HADT and HEAT peptides also occurred
using mAbs 7D8 and 8G9. Although the presence of glutamyl and
aspartyl residues (E73 andD74)was required for optimal antibody
binding, the presence of D74 was absolutely necessary to maintain
a high-afﬁnity interaction.
The ex vivo reactivity of mAbs 2A4, 7D8, and 8G9 with amyloid
was demonstrated immunohistochemically, as seen when the con-
gophilic birefringent deposits present in the liver, spleen, kidney,
and pancreas of AAmice, as well as humanAAamyloid-containing
tissues, were immunostained with these reagents. In all instances,
the 2A4 antibody exhibited the most intense binding that, notably,
was abolished by absorption with the GHEDT-containing peptide
used for immunization (Figure 4).
FIGURE 6 | Biodistribution of mAbs in healthy, amyloid-free mice. SPECT/CT images obtained 48 h after animals were injected with∼250μCi of 125I-labeled
mAbs 2A4, 7D8, and 8G9. No accumulation of the radiotracers was detected in healthy organs. Arrows indicate the presence in the thyroid of free iodide
liberated during catabolism.
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The capability of mAbs 2A4, 7D8, and 8G9 to bind AA amy-
loid in vivo also was assessed using radioiodinated derivatives of
the three reagents which, when labeled with I-125, had a radio-
chemical yield of ∼50% and a speciﬁc activity of ∼25μCi/μg.
H2-Ld-huIL-6 mice with extensive systemic AA amyloidosis were
given 200μl tail vein injections of a solution containing∼10μg of
radiolabeled antibody (∼250μCi) in PBS and imaged 48 h later.
As seen by high-resolution SPECT, there was marked uptake of
the radiotracers in the liver, spleen (Figure 5) and, to a lesser
extent, other amyloid-containing areas, e.g., kidneys and intes-
tine. In contrast, there was no visualization of the amyloid in
transgenic mice that received the control radioiodinated antibody
(since the animals were not pre-treatedwith Lugol’s solution, there
was thyroidal uptake of free radioiodide liberated during anti-
body catabolism). Further, the radiolabeled mAbs did not bind to
amyloid-free organs or tissues from healthy mice (Figure 6).
FIGURE 7 | Specific in vivo binding of radiolabeled AA fibril-specific mAbs to AA amyloid. Comparison of Congo red (CR)-stained tissue sections with
autoradiographs (ARG) of murine AA deposits in liver, spleen, and renal papilla from H2-Ld-huIL-6 mice given i.v. injections of 125I-labeled mAbs 2A4, 7D8, or 8G9.
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Table 2 | Biodistribution of radiolabeled mAbs in AA amyloidotic or control mice.
2A4 7D8 8G9 MOPC 141
Mean % ID/g SD Mean % ID/g SD Mean % ID/g SD Mean % ID/g SD
Skin 0.29 0.07 0.20 0.06 0.16 0.09 0.07 0.04
Muscle 0.24 0.08 0.18 0.06 0.16 0.08 0.05 0.04
Liver 30.77 5.96 22.66 4.38 22.87 7.07 0.19 0.08
Spleen 55.71 4.37 46.00 15.00 41.84 23.44 0.20 0.15
Pancreas 1.36 0.43 1.31 0.83 0.85 0.36 0.14 0.09
Kidney 1.45 0.38 1.14 0.22 3.74 3.36 0.44 0.27
Upper stomach 0.94 0.57 0.44 0.17 0.53 0.12 0.24 0.13
Lower stomach 1.35 0.65 0.77 0.34 1.01 0.56 0.31 0.16
Upper intestine 1.45 0.56 1.26 0.55 1.23 0.59 0.12 0.08
Middle intestine 0.69 0.17 0.46 0.20 0.58 0.11 0.12 0.07
Lower intestine 0.59 0.20 0.39 0.17 0.70 0.31 0.11 0.06
Heart 0.74 0.07 0.72 0.31 0.77 0.51 0.25 0.20
Lung 1.22 0.52 1.39 0.75 1.27 0.65 0.40 0.29
Tongue 0.85 0.31 0.87 0.28 0.64 0.45 0.18 0.09
Brain 0.07 0.02 0.06 0.02 0.07 0.04 0.03 0.02
N=3 mice for each mAb.
The speciﬁc localization of the 125I-labeled mAbs within
amyloid was evidenced autoradiographically, where dense black
deposits were seen around hepatic vasculature and sinusoids,
splenic follicles, and renal papilla (Figure 7), as well as other
anatomic sites deemed to contain this pathologicmaterial basedon
Congo red staining. The control radioiodinated mAb did not label
the amyloid deposits and was evident only within renal tubules.
These results were conﬁrmed by biodistribution measurements
that revealed the liver and spleen of animals injected with 125I-
labeled mAbs 2A4, 7D8, and 8G9 to contain∼25 and∼45% ID/g
of mAb, respectively, as compared to <1% ID/g with the control
(Table 2). The ratio of tissue to muscle uptake in these two organs
also was signiﬁcantly greater in mice that received the three mAbs
(∼100:1 and 200:1, respectively; Table 3). In the case of the pan-
creas and small intestine, the ratios were two- to three-fold higher,
as well.
DISCUSSION
The amyloidogenic SAA protein precursor is a 103 amino acid,
acute phase reactant lipoprotein synthesized in the liver; when
isolated from amyloid deposits, it has been cleaved proteolytically
by cathepsin-like enzymes into N-terminal fragments consisting
predominantly of∼75 residues (Yamada et al., 1995; Röcken et al.,
2005,2006). ThemAbs 2A4,7D8, and 8G9were generated,using as
immunogen the GHEDT sequence representing the 5 C-terminal
residues of murine AA (71–75), and their speciﬁcity for this site
was evidenced by the nanomolar EC50 binding values achieved
with murine, as well as human AA, and similar to that of the pep-
tide used for immunization. Notably, these two proteins, as well as
SAA of other mammals (e.g., domestic cat, cheetah, and Shar-Pei
dog), have identical amino acids at positions 73 and 74 (Figure 1),
i.e., glutamic acid and aspartic acid. Given the comparable afﬁnity
of the mAbs for murine and human AA amyloid, we posit that
their binding is based upon an interaction with this common ED
Table 3 |Tissue:muscle ratios for mice with AA amyloidosis injected
with 125I-labeled anti-AA or control mAbs.
2A4 7D8 8G9 MOPC 141
Muscle 1.0 1.0 1.0 1.0
Skin 1.2 1.1 1.0 1.4
Liver 128.2 125.9 142.9 3.8
Spleen 232.1 255.6 261.5 4.0
Pancreas 5.7 7.3 5.3 2.8
Kidney 6.0 6.3 23.4 8.8
Upper stomach 3.9 2.4 3.3 4.8
Lower stomach 5.6 4.3 6.3 6.2
Upper intestine 6.0 7.0 7.7 2.4
Middle intestine 2.9 2.6 3.6 2.4
Lower intestine 2.5 2.2 4.4 2.2
Heart 3.1 4.0 4.8 5.0
Lung 5.1 7.7 7.9 8.0
Tongue 3.5 4.8 4.0 3.6
Brain 0.3 0.3 0.4 0.6
Calculated using the data inTable 2.
sequence, as supported by results with Ala-substituted peptides
where E73A and, in particular, D74A dramatically reduced the
reactivity of each of the mAbs with the immunogen.
The ﬁbril-related speciﬁcity of the three mAbs also was evi-
denced by the fact that they bound only to the truncated AA
peptide found in amyloid ﬁbrils, but not the circulating native
protein; furthermore, the longer peptide, GHEDTMADQE span-
ning the cleavage site, did not block the interaction between the
mAbs and AA amyloid adsorbed onto microplate wells or that
present in tissue sections. Notably, the AA epitope recognized
by mAbs 2A4, 7D8 and 8G9 located between residues 71–75 is
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structurally accessible, and not blocked by molecules typically
associated with amyloid deposits, e.g., proteoglycans, apolipopro-
teins, and serum amyloid P-component (Alexandrescu, 2005),
that could potentially hinder or prevent antibody-ﬁbril binding.
Although proteolysis of the precursor protein is common in amy-
loid ﬁbrils (Bohne et al., 2004; Monti et al., 2005; Röcken et al.,
2006; Enqvist et al., 2009), this is the ﬁrst example of ﬁbril-speciﬁc
mAbs that target a neo-epitope formed as a result of proteolytic
cleavage. In contrast, other reported anti-ﬁbril-mAbs bind confor-
mational epitopes present on the non-native, ﬁbrillar form of the
amyloid precursor protein, but not the native, soluble, circulating
molecule (O’Nuallain et al., 2005, 2007).
Small animal imaging, together with micro-autoradiography,
provide an exquisitely sensitive method to determine the in vivo
biodistribution and speciﬁcity of amyloid-binding reagents. Using
the transgenic H2-Ld-huIL-6 Tg Balb/C murine model of AA
amyloidosis, inwhich animals develop spontaneous, extensive, sys-
temic deposits and have circulating SAA levels of >1mg/ml (Wall
et al., 2008), we demonstrated that each of our mAbs localized
speciﬁcally to the amyloid occurring in the liver, spleen, pancreas,
kidneys, heart, and intestines. The concentration of the antibodies
in the major sites of deposition, i.e., liver and spleen, was sufﬁ-
cient to be readily visualized by SPECT imaging and was further
demonstrated by increased tissue:muscle ratios.
CONCLUSION
The highly speciﬁc targeting of amyloid by our three mAbs, along
with the lack of binding to circulating SAA or healthy (amyloid-
free) tissues, suggest that these radiolabeled antibodies have diag-
nostic utility as imaging agents in patients with AA amyloidosis.
Additionally,given that other ﬁbril-speciﬁcmAbshave been shown
toopsonize and effect removal of pathologic light chainorAβ amy-
loid (Bard et al., 2000, 2003; Hrncic et al., 2000; Schroeter et al.,
2008), our anti-AA reagents also may have therapeutic potential.
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